Name
CN Bio
What We Do
CN Bio is a leading Organ-on-a-Chip (OOC) company enabling toxicology teams to generate more predictive, human-relevant risk assessment data earlier in drug discovery and development. Its FDA-recognized PhysioMimix® platform recreates key aspects of human liver, gut, lung, immune and multi-organ biology, helping researchers predict toxicity, investigate mechanisms of injury, and understand pharmacokinetic drivers. CN Bio is recognized for its DILI expertise where human and cross-species liver-on-a-chip models support confidence in regulatory progression. Our technology is trusted by 16 of the world’s leading pharma companies and has supported regulatory submissions, including a world-first clinical filing for metabolic liver disease. It has also contributed to major regulatory and standardization initiatives, such as the 3RsC-FDA Cross-Platform DILI Project. Together, we are helping shift safety assessment from animal-dependent testing toward more predictive, human-relevant science.
Website
Product or Service Categories (15)
Acute Toxicology, Biotechnology, Chemical Toxicology, Genotoxicity, Mechanistic Toxicology, Pharmaceutical Toxicology, Respiratory Toxicology, ADME (Absorption/Distribution/Metabolism/Excretion), Cells/Tissue, CRO—Contract Research Organization, In Vitro, Metabolism Studies, Efficacy Testing, Instruments, Research/Testing